Wednesday, October 28, 2026Eastern Time · Updated through the dayRSS

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Lilly's retatrutide outperforms Ozempic in phase 3 diabetes trial

MH

By Maren Holt · Senior Reporter, GLP-1

Oct 28 06:47 ETSource: StreetInsider

From the source

Lilly's retatrutide outperforms Ozempic in phase 3 diabetes trial

Read at streetinsider.com

Source URL https://www.streetinsider.com/Corporate+News/Lillys+retatrutide+outperforms+Ozempic+in+phase+3+diabetes+trial/27244299.html

Prescribed peptides from $99/moSee all →